(Q39740447)

14 September 2017

Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution (English)

1 reference

14 September 2017

vaccinia virus

1 reference

C Jackaman

1

1 reference

14 September 2017

D J Nelson

series ordinal

2

1 reference

14 September 2017

12 February 2010

1 reference

14 September 2017

1 reference

14 September 2017

17

1 reference

14 September 2017

429-440

1 reference

14 September 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2009.85

14 September 2017

0 references

cites work

Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Therapy of cancer by cytokines mediated by gene therapy approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Gene-based vaccines and immunotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Cancer gene therapy by adenovirus-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Clinical application of lentiviral vectors - concepts and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Viral vectors: from virology to transgene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Viral vectors in cancer immunotherapy: which vector for which strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Clinical safety of a viral vector based prostate cancer vaccine strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Cytokine production and antitumor effect of a nonreplicating, noncytopathic recombinant vaccinia virus expressing interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Interleukin-12 induces an effective antitumor response in malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Construction of recombinant fowlpox viruses as vectors for poultry vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

A convenient and reliable IL-2 bioassay using frozen CTLL-2 to improve the detection of helper T lymphocyte precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Infection with vaccinia virus alters regulation of cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Transient decreases in human T cell proliferative responses following vaccinia immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

7 January 2021

Cytokine gene therapy or infusion as treatment for solid human cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

7 January 2021

Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

7 January 2021

Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

7 January 2021

Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

7 January 2021

General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

7 January 2021

Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

7 January 2021

Malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

7 January 2021

Use of recombinant viruses to deliver cytokines influencing the course of experimental bacterial infection

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.85

7 January 2021

Identifiers

DOI

10.1038/CGT.2009.85

1 reference

Dimensions Publication ID

14 September 2017

1022036783

0 references

Fatcat ID

release_547prf74z5eqrmzsewuzws5kc4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/547prf74z5eqrmzsewuzws5kc4

24 November 2022

mapped directly with Wikidata item

1 reference